• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.完美的转化医学：优化肺癌中ALK靶向治疗的应用
Clin Cancer Res. 2014 Nov 15;20(22):5576-8. doi: 10.1158/1078-0432.CCR-14-2306. Epub 2014 Sep 16.
2
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.两种新的ALK突变介导对下一代ALK抑制剂阿来替尼的获得性耐药。
Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.
3
Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.间变性淋巴瘤激酶（ALK）抑制剂治疗失败后晚期ALK阳性非小细胞肺癌中的ALK激酶结构域突变：分析与文献综述
Clin Lung Cancer. 2016 Sep;17(5):e77-e94. doi: 10.1016/j.cllc.2016.03.005. Epub 2016 Mar 30.
4
Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.阿来替尼治疗转移性ALK重排非小细胞肺癌的安全性。
Expert Opin Drug Saf. 2017 Apr;16(4):509-514. doi: 10.1080/14740338.2017.1299706. Epub 2017 Mar 3.
5
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.CH5424802，一种选择性的 ALK 抑制剂，能够阻断耐药性的守门员突变体。
Cancer Cell. 2011 May 17;19(5):679-90. doi: 10.1016/j.ccr.2011.04.004.
6
ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.ALK F1174V突变使患者对阿来替尼敏感，而ALK I1171突变则使患者对阿来替尼耐药。疾病进展后进行系列活检的重要性。
Lung Cancer. 2016 Jan;91:70-2. doi: 10.1016/j.lungcan.2015.09.006. Epub 2015 Sep 12.
7
Alectinib for treatment of ALK-positive non-small-cell lung cancer.阿来替尼用于治疗ALK阳性非小细胞肺癌。
Future Oncol. 2017 Feb;13(4):321-335. doi: 10.2217/fon-2016-0386. Epub 2016 Oct 26.
8
The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.阿来替尼在晚期ALK重排非小细胞肺癌治疗中的作用。
Expert Rev Anticancer Ther. 2016 Dec;16(12):1227-1233. doi: 10.1080/14737140.2016.1249857. Epub 2016 Nov 3.
9
Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation.克服G1202R间变性淋巴瘤激酶耐药突变的抑制剂的发现
J Med Chem. 2015 Dec 10;58(23):9296-9308. doi: 10.1021/acs.jmedchem.5b01136. Epub 2015 Nov 25.
10
Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.ALK 激酶结构域的激活突变赋予 NPM-ALK 阳性间变大细胞淋巴瘤对结构上无关的 ALK 抑制剂的耐药性。
J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98. doi: 10.1007/s00432-014-1589-3. Epub 2014 Feb 8.

引用本文的文献

1
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.用于指导肺腺癌一线靶向治疗和进展后联合治疗策略的突变检测
Expert Rev Mol Diagn. 2016 Jul;16(7):737-49. doi: 10.1080/14737159.2016.1181545. Epub 2016 May 26.
2
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.治疗ALK阳性非小细胞肺癌患者：最新证据与管理策略
Ther Adv Med Oncol. 2015 Sep;7(5):274-90. doi: 10.1177/1758834015590593.
3
Lung cancer in the era of precision medicine.精准医学时代的肺癌
Clin Cancer Res. 2015 May 15;21(10):2213-20. doi: 10.1158/1078-0432.CCR-14-2748.

本文引用的文献

1
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.两种新的ALK突变介导对下一代ALK抑制剂阿来替尼的获得性耐药。
Clin Cancer Res. 2014 Nov 15;20(22):5686-96. doi: 10.1158/1078-0432.CCR-14-1511. Epub 2014 Sep 16.
2
Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.下一代测序揭示了一种新型 NSCLC ALK F1174V 突变，并证实 ALK G1202R 突变使对克唑替尼治疗后进展的 ALK 重排 NSCLC 患者对艾乐替尼（CH5424802/RO5424802）具有高水平耐药性。
J Thorac Oncol. 2014 Apr;9(4):549-53. doi: 10.1097/JTO.0000000000000094.
3
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.ALK 抑制剂色瑞替尼克服非小细胞肺癌的克唑替尼耐药性。
Cancer Discov. 2014 Jun;4(6):662-673. doi: 10.1158/2159-8290.CD-13-0846. Epub 2014 Mar 27.
4
Ceritinib in ALK-rearranged non-small-cell lung cancer.塞瑞替尼治疗间变性淋巴瘤激酶重排的非小细胞肺癌。
N Engl J Med. 2014 Mar 27;370(13):1189-97. doi: 10.1056/NEJMoa1311107.
5
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.克唑替尼与化疗用于治疗晚期 ALK 阳性肺癌。
N Engl J Med. 2013 Jun 20;368(25):2385-94. doi: 10.1056/NEJMoa1214886. Epub 2013 Jun 1.
6
ALK in lung cancer: past, present, and future.ALK 在肺癌中的过去、现在和未来。
J Clin Oncol. 2013 Mar 10;31(8):1105-11. doi: 10.1200/JCO.2012.44.5353. Epub 2013 Feb 11.
7
Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.ALK 抑制逃逸：克服耐药性的机制和策略。
Sci Transl Med. 2012 Feb 8;4(120):120ps2. doi: 10.1126/scitranslmed.3003728.
8
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.ALK 重排肺肿瘤获得性克唑替尼耐药的机制。
Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
9
Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.通过加速诱变筛选鉴定出的 EML4-ALK 耐药突变体。
Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
10
Identification of ALK as a major familial neuroblastoma predisposition gene.将ALK鉴定为主要的家族性神经母细胞瘤易感基因。
Nature. 2008 Oct 16;455(7215):930-5. doi: 10.1038/nature07261. Epub 2008 Aug 24.

完美的转化医学：优化肺癌中ALK靶向治疗的应用

Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer.

作者信息

Politi Katerina, Gettinger Scott

机构信息

Departments of Pathology and Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.

Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.

出版信息

Clin Cancer Res. 2014 Nov 15;20(22):5576-8. doi: 10.1158/1078-0432.CCR-14-2306. Epub 2014 Sep 16.

DOI:10.1158/1078-0432.CCR-14-2306
PMID:25228532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4401422/
Abstract

Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.

摘要

ALK突变是ALK重排肺癌对小分子ALK抑制剂获得性耐药的常见机制。不同的突变体对ALK抑制剂表现出不同的敏感性。使肿瘤的突变谱与合适的ALK抑制剂相匹配，对于使患者最大程度获益可能至关重要。